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THE true value of an apparently effective chemotherapeutic agent in the treat-
ment ofmalignantdisease can be assessed only afterit has been in use for a consider-
able period of time. This paper summarises the authors' early experiences with
vinblastine sulphate, an alkaloid which has been reported on favourably as an
oncolytic agent (Warwick, Darte and Brown, 1960; Hodes, Robin and Bond,
1960). Unfortunately, early workers have also indicated that side effects could
be severe.
Patients
In the first two years, 126 patients with advanced malignant disease have
received treatment. Most ofthem suffered from one ofthe malignant lymphomas
but patients with other cancers were also treated (Table I).
TABLE I.- Vinblastine by Intermittent Intravenous Injection
Tumour type
Hodgkin's disease
Lymphosarcoma
Reticulum sarcoma
Acute leukaemia
Multiple myeloma
Unclassified reticuloses
Breast carcinoma
Bronchial carcinoma
Malignant melanoma
Carcinomatosis-
(primary unknown)
Ewing's sarcoma
Malignant thymoma
Leiomyosarcoma
Pancreatic carcinoma
All types
Objective
Good Moderate
24 2
1
* 1 1
2
1
Response
Sub-
jective
4
3
3 2
_ 2
1
1 . -
1
1
- . 1
30 8 12 41 91
Several methods of administration of the drug were adopted, but most patients
received vinblastine by intermittent intravenous injection. Although a response
was sometimes seen in the first few days of treatment, it was not always clearly
apparent until after 3-4 weeks. Treatment with vinblastine for less than 4 weeks
for any reason, was therefore considered to be inadequate.
None
8
3
3
3
1
4
.9
2
4
Patient
Total
38
4
8
3
1
1
11
12
3
1
1
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This report is concerned primarily with the intermittent intravenous use of
vinblastine, as this seems to be the most generallyusefulmethod ofadministration,
and 91 of 116 patients treated in this way were considered to have received enough
to allow a reasonable assessment ofthe response ofthe tumour and ofthe patient
to the drug (Table II).
TABLE II.-Vinblastine Administration by all methods
Patients receiving Vinblastine . . . 126
Intra-arterial infusion . . . . . 5
Intra-pleural and peritoneal instillation . . . 3
Intravenous infusion . . . . . 2
Intermittent intravenous injection . . . 116
Intermittent intravenous injection for over 4 weeks . 91
Administration and dosage
There was considerable variation in the reaction ofeach individual to the drug,
and it was impossible to give a standard dose to all patients. The maximum dose
tolerated by each individual was found by following each injection for 5-7 days,
before considering further treatment.
The first injection was usually of 10 mg. and if no serious untoward effects
followed, this was increased to 15 andthen 20 mg. No patient toleratedmorethan
20 mg. in one injection. Injections were continued at weekly intervals, the dose
depending upon the tolerance ofthe individual, until either the maximum benefit
was obtained, or toxic effects occurred. The time interval between injections
was then gradually increased.
Some of our earlier patients relapsed when the drug was stopped after a satis-
factory remission and this relapse was often followed by the development of drug
resistance. Our present practice is to continue with monthly injections for as
long as the remission continues. To date, there have been no cumulative side
effects.
Complications
Early reports on the use ofvinblastine suggested that it was an extremely toxic
substance, and this would appear to be confirmed by the impressive list ofcompli-
cations that occurred in our patients (Table III). This formidable listis compre-
hensive, including many patients whose symptoms were mild, and in practice
TABLE Ill.-Complications of Vinblastine by Intermittent Intravenous Injection
Leucopenia . . . . . 18
Thrombocytopenia . . . 1
Nausea and/or vomiting . . . . 10
Abdominal colic . . . . 4
Severe constipation . . . 1
Ileus (laparotomy) . . . . 1
Alopecia (temporary) . 9
Joint pains, paraesthesiae . . . 12
General weakness, malaise, depression . . . 5
Alteration of taste . . . . . 1
Painful lymph nodes . . . . 1
Total number of patients affected by complications . 37N. M. BLEEHEN AND A. M. JELLIFFE
vinblastine is one of the least toxic oncolytic drugs thatwe haveused. Themost
interesting feature ofthese side effects is that several appear to be due to a neuro-
toxic effect which is not seen in agents of unrelated chemical structure.
Local effects
Vinblastine is extremely soluble and the dose can be dissolved in as little as
1 c.c. of water. Intravenous injection is not followed by thrombophlebitis, but
extravenous injection leads to an extremely painful swelling which may take
several weeks to subside. Pain is produced almost immediately if extravasation
occurs, and we have found that a useful safeguard is to wait after injecting a very
small quantity, before giving the whole dose. The production of pain indicates
a leak, and that particular injection must not proceed further.
Haematopoietic depression effects
Depression of the bone marrow is common during the administration of active
oncolytic agents, and vinblastine is no exception. However, depression of the
white cell count is usually maximal at about one week. The dose can be gradually
increased until there is a fall to between 3000 and 4000 totalwhite cells. The use of
this drug was rarely prevented by haematopoietic depression, and a serious, acute
fall in the white cell count is followed, as a rule, by an equally rapid recovery.
Only two patients in this series have had severe haematopoietic depression which
probably affected their survival and both had been treated previously with other
oncolytic agents.
GCastro-intestinal effects
These and the neurotoxic effects were most commonly seen 36-48 hours after
the injection. We are unable to explain this delay. Nausea, with or without
vomiting, was tiresome in a few patients, but never prevented adequate treatment.
Alteration of taste, similar to that occasionally seen with other drugs such as the
alkylating agents, occurred only once and was of no importance. The other
gastro-intestinal effects encountered are unlike those seen with most other agents
and we relate them to the neurotoxic effects.
Neurotoxic effects
Peculiar paraesthesiae, cramps and joint pains were sometimes so severe that
they became the limiting factor in the treatment. Minor aches and pains were
very common but were usually ignored by the patients, unless specifically enquired
after. Increasing the dose led to more pain, and there was a direct relationship
between dose level and degree of pain in each individual. Colicky abdominal
pains were associated with abdominal distension and sometimes constipation:
one patient developed extreme distension and was admitted as an emergency, for
investigation, to another hospital without our knowledge. A possible association
between his symptoms and previous treatment was, unfortunately, not considered
and a laparotomy was performed for intestinal obstruction. At operation the
whole bowel was grossly distended, so much so that the abdominal cavity was
closed with considerable difficulty, but the patient made a rapid, uneventful
recoverv.
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Alopecia
This complication occurred in 9 patients, but in none was it complete. Hair
grew again rapidly on stopping the agent, and resumption of treatment did not,
interfere with this process in 7 patients. One patient continued to lose hair until
the dose was reduced to 10 mg. weekly. Only one patient was left with sparsely
growing hair and he had previously lost all his scalp hair following a course of
cyclophosphamide 8 months previously.
General effects
Vague general symptoms were not uncommon, maximal 3f-48 hours after
each injection and rarely lasting for longer than 2-3 days. A few patients found
these symptoms limited their activities during this period of time, but usually
they were referred to by the patient only if specifically questioned.
Tumour Response
Hodgkin's disease
With most oncolytic agents, more satisfactory responses are seeninHodgkin's
disease than in any other condition, and vinblastine is no exception. All patients
treated had advanced disease withgeneralised lymph node enlargement, and some-
times invasion of extra-lymphatic structures. A good response was usually
obvious within 1-2 weeks of starting treatment. Fluctuations in the natural
course of the disease make it impossible to attribute an improvement ofless than
4 weeks to any specific treatment, and an improvement was therefore recorded
as such only if it continued steadily for at least this period of time. A " good "
response in this condition indicates general improvement with disappearance of
enlargednodesandspleen, andamoderateresponse indicates generalimprovement,
with a reduction in size ofnodes or spleen to under halftheir original size. Remis-
sions of 1-20 monthshave occurred, thelongest to date being20months,thepatient
continuing in remission. The average period of good objective control was
7 months.
A good remission occurred more frequently when the Hodgkin's disease was
known to have responded previously to other agents, and aresponsewasmuch less
likely when the tumour had proved refractory to treatment with other drugs
(Table IV). This limits the usefulness ofvinblastine, but nevertheless some remis-
TABLE IV.-Response to Vinblastine after Previous Administration of Other
Agents
Response to previous Subsequent response
chemotherapeutic agents to vinblastine
Good-13 patients . . None-6 patients
Good-7 patients
None 10 patients . . None-7 patients
Good-3 patients
sions followed failure to control the disease by other means. In addition, vinblas-
tine is particularly indicated when haematopoietic depressionmakes the adminis-
tration ofmany other agents extremely hazardous. Ingeneral, we regard vinblas-
tine as the most effective and least toxic of the available agents for the control
of systemic Hodgkin's disease.
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Other lymphomras
Patients with lymphosarcoma and reticulum sarcoma sometimes respond well
to vinblastine, but less frequently than with Hodgkin's disease (Table I). Our
results sofar suggest thatthe drug ofchoice in the management oftheselymphomas
is still an alkylating agent, chlorambucil being the most generally satisfactory and
least toxic. But it is well worth trying vinblastine if more conventional drugs
are not controlling the disease.
Non-lymphomatous tumours
Various other types of cancer were treated with vinblastine, with little success.
One bronchial carcinoma decreased in sizefor aperiod of6 weeksand onemalignant
thymoma regressed for a similar period of time.
Generalised breast cancer has been reported to respond to vinblastine
(Armstrong, Dyke and Fouts, 1962) but in our experience the results have been
very disappointing. Two patients showed a marked response, but the final
result was unsatisfactory. One required 20 mg. weekly to control the disease
and this dose level could not be maintained because ofhaematopoietic depression.
Thesecond patient had extensivetumour involving both breastsandspreadingover
the whole of the chest wall. There was a remarkable improvement for 12 weeks,
when the patient lapsed from treatment. Within 3 weeks the tumour spread
rapidly and it now proved resistant to large doses of vinblastine.
DISCUSSION
Vinblastine given by intermittent intravenous injection is undoubtedly a highly
effective drug in the management of various generalised malignant lymphomas,
and at present it appears to us to be the treatment of choice in the control of
advanced, Stage III, Hodgkin's disease (Jelliffe and Thomson, 1952).
Various toxic effects occur, some quite commonly, but on the whole the drug
is remarkably free from unpleasant side effects. In our experience, all oncolytic
agents at present in clinical use have various tiresome side effects, some of which
may not be related by the patient to that drug, until a particular course of treat-
ment has stopped. Vinblastine is no exception and many patients refer later to
vague symptoms which they had noticed, but which had not distressed them
during the period of its administration. Most patients notice a sense of general
well-being and this more than makes up for vague aches and pains which they
may have.
The beneficial effects of vinblastine may occur with extreme rapidity. To
illustrate this, we refer to one patient with Stage III Hodgkin's disease which had
proved refractory to various alkylating agents. Treatment was started after the
patient had been restricted to his bedroom for 4 months. Two days after the
first injection, he dressed and went actively about the house in spite of painful
joints and muscle cramps, and he noticed the disappearance of the irritation and
sweating which had been a regular nightly feature. Four days after starting
treatment his wife telephoned to see if he could be allowed to carry out minor
tasks in the garden.
Such a dramatic effect is certainly not seen in all patients, and it may be as
long as 3-4 weeks before the benefits become obvious, particularly with tumours
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which do not originate in lymphatic tissue. Nevertheless, the rapid benefits
which may follow its use permit a favourable comparison of vinblastine with
chloroethylimine as an agent for the treatment ofurgent problems in the manage-
ment of Hodgkin's disease. Vinblastine can also be most satisfactory in the long
term control of this disease, and it is particularly useful when there is already
evidence of depression of the haematopoietic system.
The greatest practical disadvantages of vinblastine are the need for regular
intravenous injections, and the extremely painful reactions which inevitably
follow any extravasation of the drug. There are patients who have no superficial
veins of any reasonable size and rarely this has forced us to abandon the use of
vinblastine.
This report refers essentially to the use ofvinblastine sulphate by intermittent
intravenous injection in the management ofgeneralised malignant disease. When
given by intra-arterial infusion, a very powerful cancerocidal effect can be
produced in the area supplied by that artery and this use of vinblastine will be
referred to elsewhere. When given systemically the oncolytic effect is, of course
very much less marked. It is important to emphasise that vinblastine, and all
other oncolytic drugs given systemically, are totally unsatisfactory substitutes
for energeticradiotherapy inthe attemptedradicaltreatment oflocalisedmalignant
lymphomas and it is clear that surgery remains the most hopeful method oftreat-
ment in the attempted cure ofrelatively radio-resistant, operable tumours arising
elsewhere.
SUMMARY
Vinblastine sulphate is an extremely active oncolytic agent. Tumour control
can be obtained with only minor side effects. The toxic effects of this drug
suggest that its mode of action is very different from other previously reported
agents. The most striking effects are produced in Hodgkin's disease, in the
treatment of which it may be the present drug of choice, but regression of other
tumours can be produced. Further long-term study of the drug is indicated
before its real value can be decided.
As with all other known oncolytic agents, the systemic administration of
vinblastine sulphate is not a substitute for radiotherapy or surgery in the radical
treatment of localised tumours.
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